Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.
A NON-RANDOMIZED, OPEN-LABEL, THREE-PART, DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECTS OF ITRACONAZOLE, CARBAMAZEPINE, AND QUINIDINE ON THE PHARMACOKINETICS AND SAFETY OF EDP-235 IN HEALTHY PARTICIPANTS
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Guy De La Rosa, MD
- Phone Number: 617 607 0800
- Email: gdelarosa@enanta.com
Study Locations
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
- ICON, plc.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- An informed consent document signed and dated by the subject
- Healthy male and female subjects of any ethnic origin between the ages of 18 and 55 years, inclusive
- Screening body mass index (BMI) of 18 to 30 kg/m2 with a minimum body weight of 50 kg
- Female subjects of childbearing potential must agree to use two effective methods of contraception from the date of Screening until 90 days after the last dose of EDP-235. A male participant who has not had a vasectomy and is sexually active with a woman of childbearing potential must agree to use effective contraception from the date of Screening to 90 days after his last dose of study drug.
Exclusion Criteria:
- Clinically relevant evidence or history of illness or disease
- Pregnant or nursing females
- History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection
- A positive urine drug screen at Screening or Day -1
- Current tobacco smokers or use of tobacco within 3 months prior to Screening.
- Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy)
- History of regular alcohol consumption
- Participation in a clinical trial within 30 days prior to the first dose of study drug
For Part 2 participants:
- Participants of Asian ancestry, given association of carbamazepine and severe rash (Stevens-Johnson Syndrome [SJS and Toxic Epidermal Necrolysis [TEN]) with HLA-B 1502 in this population
- Platelets, white blood cell count or hemoglobin below the lower limit of normal, due to reported incidence of agranulocytosis and aplastic anemia with carbamazepine.
For Part 2 and Part 3 participants, the following cardiovascular abnormalities:
- QRS duration >110 ms
- Incomplete right bundle branch block or any complete bundle branch block
- Heart rate <40 or >90 beats per minute (per vital sign capture while rested)
- History of unexplained syncope, structural heart disease, or clinically significant arrhythmias
- Personal or family history of long QT syndrome (genetically proven or suggested by sudden death of a close relative due to cardiac causes at a young age) or Brugada syndrome
- PR interval >220 ms or any 2nd or 3rd degree AV block
- Ventricular pre-excitation
- History of drug allergy to itraconazole or other azole antifungals; history of drug allergy to carbamazepine or carboxamide derivatives [e.g. oxcarbazepine]; known hypersensitivity to drugs structurally related to carbamazepine [e.g.: tricyclic antidepressants] or any of its excipients);history or known hypersensitivity to mefloquine, quinine, or quinidine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: EDP-235 and Itraconazole interaction (Part 1)
Subjects will receive EDP-235 and Itraconazole on respective dosing days
|
Subjects will receive EDP-235 on Days 1 and 14
Subjects will receive EDP-235 on Days 1 and 23
Subjects will receive EDP-235 on Days 1 and 8
Subjects will receive itraconazole QD Days 5-18
|
|
Experimental: EDP-235 and Carbamazepine interaction (Part 2)
Subjects will receive EDP-235 and Carbamazepine on respective dosing days
|
Subjects will receive EDP-235 on Days 1 and 14
Subjects will receive EDP-235 on Days 1 and 23
Subjects will receive EDP-235 on Days 1 and 8
Subjects will receive carbamazepine BID Days 5-23 and Days 24-27
|
|
Experimental: EDP and Quinidine interaction (Part 3)
Subjects will receive EDP-235 and Quinidine on respective dosing days
|
Subjects will receive EDP-235 on Days 1 and 14
Subjects will receive EDP-235 on Days 1 and 23
Subjects will receive EDP-235 on Days 1 and 8
Subjects will receive quinidine BID Days 5-12
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cmax of EDP-235 with and without coadministration with Itraconazole
Time Frame: Day 1 through Day 19
|
Day 1 through Day 19
|
|
AUC of EDP-235 with and without coadministration with Itraconazole
Time Frame: Day 1 through Day 19
|
Day 1 through Day 19
|
|
Cmax of EDP-235 with and without coadministration with Carbamazepine
Time Frame: Day 1 through Day 26
|
Day 1 through Day 26
|
|
AUC of EDP-235 with and without coadministration with Carbamazepine
Time Frame: Day 1 through Day 26
|
Day 1 through Day 26
|
|
Cmax of EDP-235 with and without coadministration with Quinidine
Time Frame: Day 1 through Day 13
|
Day 1 through Day 13
|
|
AUC of EDP-235 with and without coadministration with Quinidine
Time Frame: Day 1 through Day 13
|
Day 1 through Day 13
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety measured by adverse events
Time Frame: Up to 34 days
|
Up to 34 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Anti-Infective Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Anticonvulsants
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Antimanic Agents
- Cytochrome P-450 CYP2D6 Inhibitors
- Hormone Antagonists
- Cytochrome P-450 Enzyme Inducers
- Antifungal Agents
- Steroid Synthesis Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Cytochrome P-450 CYP3A Inducers
- Antimalarials
- 14-alpha Demethylase Inhibitors
- Adrenergic alpha-Antagonists
- Itraconazole
- Carbamazepine
- Quinidine
Other Study ID Numbers
Other Study ID Numbers
- EDP 235-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.